EPIVAX, INC.
Address
PROVIDENCE, RI, -
Information
| DUNS: | 135531015 |
| # of Employees: | N/A |
Ownership Information
| Hubzone Owned: | N |
| Socially and Economically Disadvantaged: | N |
| Woman Owned: | N |
Award Charts
Award Listing
-
Record 1 TO 13
-
Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza
Amount: $300,000.00DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic ...
SBIRPhase I2016Department of Health and Human Services -
EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of
Amount: $1,474,236.00DESCRIPTION (provided by applicant): The goal of this Phase II project is to advance the development of novel tolerance-inducing peptides (Tregitopes) to prevent and/or treat Type 1 diabetes (T1D) by ...
SBIRPhase II2012Department of Health and Human Services -
Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease
Amount: $600,000.00DESCRIPTION (provided by applicant): Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease Pompe disease is a lysosomal storage disorder caused by defects in the enzyme acid alpha-glucosi ...
SBIRPhase I2012Department of Health and Human Services -
Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A
Amount: $757,712.00DESCRIPTION (provided by applicant): The goal of this new SBIR program is to produce a combined clotting Factor VIII replacement and immunomodulatory therapy that will provide FVIII-specific tolerance ...
SBIRPhase I2012Department of Health and Human Services -
T1D Tolerance Induction with Natural Treg Epitopes
Amount: $599,999.00DESCRIPTION (provided by applicant): Type 1 (juvenile) diabetes is an organ-specific autoimmune disease resulting from destruction of insulinproducing pancreatic beta-cells. In non-diabetics, islet ce ...
SBIRPhase I2008Department of Health and Human Services -
Optimization of a Multivalent Tuberculosis Vaccine
Amount: $299,908.00DESCRIPTION (provided by applicant): This new Phase I SBIR proposal addresses the continuing worldwide need for a tuberculosis (TB) vaccine. We detail a novel multivalent strategy that aims to elicit ...
SBIRPhase I2007Department of Health and Human Services -
Epitope-driven deimmunization of Factor VIII
Amount: $263,867.00DESCRIPTION (provided by applicant): Hemophilia A patients are prone to develop inhibitory immune responses to the very therapy they require: Factor VIII protein replacement. Up to 30% of all hemophil ...
SBIRPhase I2007Department of Health and Human Services -
A Genome-Derived, Epitope-Driven H. Pylori Vaccine
Amount: $609,910.00DESCRIPTION (provided by applicant): EpiVax discovers and develops epitqpe-driven vaccines by screening microbial genomes for protective epitopes. In this application, we describe a genome-based appr ...
SBIRPhase I2005Department of Health and Human Services -
Novel Smallpox Vaccine Derived from VV/VAR Immunome
Amount: $1,027,410.00DESCRIPTION (provided by applicant): EpiVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we propose to de ...
SBIRPhase I2005Department of Health and Human Services -
A GENOME-DERIVED, EPITOPE-DRIVEN TULAREMIA VACCINE
Amount: $831,922.00DESCRIPTION (provided by applicant): EpIVax specializes in the development of epitope-driven vaccines by screening whole genomes for candidate vaccine components. In this application, we describe a r ...
SBIRPhase I2004Department of Health and Human Services
